Combining CXCL10 gene therapy and radiotherapy improved therapeutic efficacy in cervical cancer HeLa cell xenograft tumor models

MING ZHAO*, QIAN MA*, JINHUI XU, SHAOZHI FU, LANLAN CHEN, BIQIONG WANG, JINGBO WU and LINGLIN YANG

Department of Oncology, Affiliated Hospital of Luzhou Medical College, Luzhou, Sichuan 646000, P.R. China

Received August 11, 2014; Accepted April 29, 2015

DOI: 10.3892/ol.2015.3281

Abstract. Radiotherapy is an important treatment method for cervical cancer, but the efficacy requires improvement. Therefore, novel methods of treatment are required. Previous data have demonstrated that the CXC chemokine ligand 10 (CXCL10) inhibits angiogenesis, induces apoptosis and causes avoidance of the S phase of the cell cycle in cervical cancer cells. The aim of the present study was to evaluate the anti-tumor effect of radiotherapy combined with CXCL10 gene therapy. Mouse models of cervical carcinoma were created by inoculation with HeLa cells, and were treated by combining intravenously administered plasmid-encoding CXCL10, administered 5 times (days 12, 15, 18, 21 and 24 following inoculation), with direct radiation (20 Gy/5 fractions) administered on 5 consecutive days (~day 27 after inoculation). The vessel density and tumor cell proliferation were observed by immunostaining, and apoptosis was determined using a TUNEL assay. The results revealed a significant increase in the inhibition of tumor growth, reduced vessel density, decreased cell proliferation and increased apoptosis in the tumor cells of the combination therapy group. Overall, these findings resulted in the conclusion that CXCL10 gene therapy in combination with radiotherapy is a novel effective therapeutic strategy for cervical cancer.

Introduction

Cervical cancer is one of the most common cancers worldwide (1) and the leading cause of cancer-associated mortality in women in developing countries (2). The treatment of cervical cancer mainly consists of surgery, chemotherapy and radiotherapy. Radiotherapy is an important therapy for cervical cancer, and it is currently administered to almost 80% of patients with cervical cancer, at various clinical stages (3,4). However, radiotherapy is not extremely effective at treating cervical cancer, particularly in patients at an advanced stage of disease (5,6). Therefore, it is necessary to identify novel methods to combine with radiotherapy to improve the efficacy of treatment.

Chemokines are a superfamily of cytokines that are important regulators of cell migration, lymphocyte recruitment and angiogenesis (7). CXC chemokine ligand 10 (CXCL10), also termed interferon-γ-induced protein 10, is a small cytokine belonging to the CXC chemokine family that was initially characterized as a chemoattractant for activated T lymphocytes. CXCL10 has been identified as a 10-kDa secreted protein induced by interferon-γ (8) in a variety of cell types, including endothelial cells, keratinocytes, fibroblasts, activated monocytes and neutrophils (9). Over previous years, studies have increasingly reported that CXCL10 plays an important role in angiogenesis and tumor growth inhibition (10-12). Our previous study revealed that CXCL10 may induce apoptosis, inhibit angiogenesis and human papillomavirus, resulting in effects against cervical cancer (13). It has also been found that CXCL10 causes the avoidance of the S phase of the cell cycle in cervical cancer cells (14), during which time the cells are least sensitive to radiation.

Therefore, it was assumed that the combination of CXCL10 gene therapy and radiotherapy may improve the inhibition of cervical cancer progression through a variety of mechanisms, to achieve effective coordination in the treatment of cervical cancer.

In the present study, human HeLa cervical carcinoma tumors were established in immunodeficient mice, and CXCL10 gene therapy and radiotherapy were administered to establish the effects on tumor growth.

Materials and methods

Cell lines. The cervical cancer HeLa cell line was obtained from the American Type Culture Collection (Manassas, VA, USA). The cells were cultured in media consisting of
Dulbecco's modified Eagle's medium (DMEM) supplemented with 2 mM L-glutamine (GE Healthcare Life Sciences, Logan, UT, USA), plus 100 U/ml penicillin and 100 µg/ml streptomycin (Beyotime Institute of Biotechnology, Haimen, Jiangsu, China), and 10% fetal bovine serum (FBS; GE Healthcare Life Sciences).

Plasmids. A DNA fragment encoding CXCL10 was cloned into the pcDNA3.1 vector (Invitrogen, Carlsbad, CA, USA) between the restriction sites for EcoRI and XhoI. The plasmid was purified by two rounds of passing over Endo-free columns (Qiagen, Valencia, CA, USA), as previously described (15).

Reverse transcription-quantitative polymerase chain reaction (PCR). Total RNA was isolated from HeLa cells transfected with the pcDNA3.1-CXCL10 plasmid using TRIzol reagent (Invitrogen), according to the manufacturer's instructions. Total RNA was reverse transcribed to cDNA using the reverse transcription system from Promega (Madison, WI, USA). PCR was subsequently performed with an initial denaturation step that was performed at 94°C for 4 min, followed by 28 cycles at 94°C for 20 s, 60°C for 20 s and 72°C for 30 s, with a final extension of 72°C for 4 min. The primers used for PCR were as follows: CXCL10 forward, 5'-CCTTATCTTTCTGACTCTAAGTGCC-3' and reverse, 5'-ACGTGGACAAAATTGGGCTTG-3'; GAPDH forward, 5'-TCATCTCTGCCCGGCTG-3' and reverse, 5'-CCTGCTTCACCACCTTCTTG-3'.

Tumor formation in nude mice. To establish the cervical cancer tumors, eight-week-old female nude mice (Beijing HFK Bioscience Co., Ltd, Beijing, China) were inoculated with 1x10⁶ HeLa cells subcutaneously in the right flank. Tumor dimensions were measured with calipers every 3 days, and tumor volumes were calculated as follows (16):

Tumor volume (mm³) = 0.5 x length x width²

Animal experiments were conducted according to institutional guidelines concerning animal use and care, and the study was approved by the ethics committee of Luzhou Medical College, (Luzhou, China).

CXCL10 gene therapy. The mice were randomly divided into five groups when the tumors were ~15 mm³ in volume, which occurred ~12 days subsequent to HeLa cell inoculation, and each group consisted of 10 mice. The recombinant CXCL10 or pcDNA3.1 plasmids were gently combined with a liposomal transfection agent in a 1:3 ratio (50:150 µg for each mouse), and incubated at room temperature for ~30 min. The mixture was then administered intravenously 5 times on days 12, 15, 18, 21 and 24. Mice from the phosphate-buffered saline (PBS) group were injected with PBS as the control agent and acted as the control group.

Radiotherapy. Radiotherapy was performed when the tumors were ~300 mm³ in volume, which occurred ~27 days subsequent to inoculation of the mice with HeLa cells. The tumors were radiated with 6-MV X-rays, and each mouse was administered with a total radiation dose of 20 Gy, with 4 Gy being administered for each dose on 5 days, at the rate of 200 cGy/min.

Histological analysis. The mice were sacrificed 39 days subsequent to inoculation with the HeLa cells and the tumors were removed and embedded in paraffin. Tissue sections were immunostained with rat anti-mouse monoclonal antibody against cluster of differentiation 31 (CD31; catalog no. 553369; BD Biosciences, Franklin Lakes, NJ, USA; dilution, 1:200) or rabbit anti-human polyclonal antibody against Ki-67 (catalog no. 19972-1-AP; Proteintech Group, Inc., Wuhan, Hubei, China; dilution, 1:100). Vessel density was calculated by counting the number of microvessels per high-power field (magnification, x200; Leica DM3000, Leica Microsystems GmbH, Wetzlar, Germany) in the tumor sections, as previously described (17). The rate of cell proliferation was calculated for five random fields by dividing the number of Ki-67-positive cells by the total number of cells. TUNEL was performed using an in situ cell-death detection kit (Roche, Mannheim, Germany). In total, five fields were randomly selected and analyzed. The apoptotic index was calculated as the ratio of the apoptotic cell number to the total tumor cell number in each field.

Statistical analysis. The data were assessed by a one-way analysis of variance and Student's t-test, and a post-hoc test was conducted according to the Student-Newman-Keuls method. P<0.05 was considered to indicate a statistically significant difference.

Results

Overexpression of CXCL10 in HeLa cells. The recombinant plasmid encoding CXCL10 was cloned, and the transcript of CXCL10 mRNA was confirmed in transfected cells, as revealed by RT-PCR.

Combination of CXCL10 gene therapy and radiotherapy markedly inhibits cervical cancer tumor growth. The effects of CXCL10 gene therapy and radiotherapy alone and in combination on xenograft tumor models of cervical cancer were assessed in nude mice. The tumor volumes were measured every 3 days subsequent to inoculation with HeLa cells. The tumor volume in the PBS and pcDNA3.1 control groups increased rapidly. By contrast, the tumor growth rate in nude mice treated with CXCL10 gene therapy alone decreased compared with the control group, and this decline...
was more evident in the group treated with radiotherapy. In addition, the combined treatment of CXCL10 gene therapy and radiotherapy inhibited tumor growth more effectively compared with all other groups (P<0.05) (Fig. 2A). Similarly, the treatment of tumors demonstrated corresponding effects on tumor weight (Fig. 2B). Overall, CXCL10 gene therapy in combination with radiotherapy significantly inhibited cervical cancer tumor growth.

**Effect of CXCL10 gene therapy and radiotherapy on angiogenesis in cervical cancer.** Immunohistochemical labeling of microvessels by CD31 in tumor sections revealed a decrease in tumor vessel density in the CXCL10 group and radiotherapy group compared with those in the control group. In combination, treatment with CXCL10 plus radiotherapy appeared more effective at reducing microvessel density compared with the other groups (P<0.05; Fig. 3).
Effect of CXCL10 gene therapy and radiotherapy on cell proliferation in cervical cancer. Cell proliferation was analyzed by immunohistochemical staining of Ki-67 in tumor sections. The number of Ki-67-positive cells were calculated and divided by the total number of cells. A slight but significant decrease in the number of Ki-67-positive cells was observed in the CXCL10 and radiotherapy groups compared with the control group (P<0.05). Additionally, a greater reduction in the number of Ki-67-positive cells was identified in the combination group (P<0.05; Fig. 4).

Figure 4. Effect of CXCL10 gene therapy and radiotherapy on cell proliferation in cervical cancer cells. Tissue specimens were obtained from the tumors treated with PBS, lipo + pcDNA3.1, lipo + CXCL10, lipo + pcDNA3.1 + radiotherapy and lipo + CXCL10+radiotherapy. The proliferation rate of tumor cells was determined by Ki-67 staining. The Ki-67 positive cells divided by the total number of cells was evidently decreased in the combination group. Error bars represent the standard error of the entire treatment group. *P<0.05 vs. controls. CXCL10, CXC chemokine ligand 10; PBS, phosphate buffered saline; lipo, liposomal transfection agent.

Figure 5. Effect of CXCL10 gene therapy and radiotherapy on cell apoptosis in cervical cancer cells. The apoptotic index was detected by TUNEL assay. The combination group, which was treated with CXCL10 gene therapy and radiotherapy, demonstrated a significant increase in apoptosis compared with the other treatment groups. Error bars express the standard error of the entire treatment group. *P<0.05 vs. controls. CXCL10, CXC chemokine ligand 10; PBS, phosphate buffered saline; lipo, liposomal transfection agent.
Effect of CXCL10 gene therapy and radiotherapy on cell apoptosis in cervical cancer. The apoptotic rate was analyzed by TUNEL assay in the five groups. As shown in Fig. 5, the cellular apoptosis rate in the CXCL10 group and radiotherapy group was found to be ~10% higher compared with the control, while the rate was even higher in the combination group compared with the CXCL10 and radiotherapy groups (P<0.05) (Fig. 5).

Discussion

Previously, CXCL10 has been demonstrated to be involved in cell cycle regulation in a podocyte cell line, with increased p27Kip1 expression and decreased cyclin E expression (18). Similar results were obtained using HeLa cells in previous studies (17). p27Kip1 and cyclin E are crucial cell cycle regulators that are involved in arresting the cell cycle at the G1 phase (19) and promoting cell cycle progression to the S phase (20), respectively. Reduced cyclin E expression prevents cell cycle transition from the G1 to S phase, so the cells remain in the G1 phase. Therefore, CXCL10 may inhibit cell proliferation by influencing cell cycle-associated proteins.

It has been demonstrated that radiation destructs genome DNA to induce cell apoptosis (21); however, S phase, during which time gene synthesis is active in tumor cells, is least sensitive to radiation (22). Therefore, avoidance of the S phase in cancer cells is important for the improvement of the efficacy of radiotherapy. On the basis of our previous analysis (14), it was assumed that CXCL10 is a crucial factor that arrests the cell cycle at G1 phase to avoid the S phase, and therefore promotes the efficacy of radiotherapy.

In the present study, treatment with liposome-encapsulated CXCL10 gene therapy and radiotherapy was combined to assess the resulting inhibition of growth in cervical cancer tumors. The present results revealed that CXCL10 gene therapy and radiotherapy each attenuated tumor growth when administered separately. In addition, the combination of the two therapies demonstrated a significantly increased inhibitory effect on tumor growth. To understand the mechanism of the growth inhibition, tumor sections were analyzed for angiogenesis, cell proliferation and apoptosis. It was found that CXCL10 gene therapy combined with radiotherapy enhances the reduction of microvessel density, decrease in cell proliferation and upregulation of apoptosis compared with each treatment alone.

Overall, the present study indicated that the combination of CXCL10 gene therapy and radiotherapy is an efficient strategy for growth suppression in cervical tumors, which may result from the attenuation of angiogenesis, decline in cell proliferation and induction of apoptosis. This approach is novel as it hypothesizes CXCL10 may enhance the radiosensitivity of cervical tumors in nude mice. Since the present protocol was not performed using any other tumor model, whether this approach may be applied to other tumor types remains unknown, and additional investigations are required.

Acknowledgements

This study was supported by grants from the National Natural Science Foundation (grant no. 81201784), Luzhou Medical College Foundation (grant no. 20130388) and Affiliated Hospital of Luzhou Medical College Foundation (grant no. 201471#).

References

1. Schiffman M and Castle PE: The promise of global cervical cancer prevention. N Engl J Med 353: 2101-2104, 2005.
2. Mandelblatt JS, Lawrence WF, Womack SM, Jacobson D, Yi B, Hwang YT, Gold K, Barter J and Shah K: Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 287: 2372-2381, 2002.
3. Small W Jr, Mell LK, Anderson P, et al: Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys 71: 428-434, 2008.
4. Grigsby PW: Radiotherapy for pelvic recurrence after radical hysterectomy for cervical cancer. Radiat Med 23: 327-330, 2005.
5. Klop AH and Eifie PF: Chemoradiotherapy for cervical cancer in 2010. Curr Oncol Rep 13: 77-85, 2011.
6. Tanderup K, Georg D, Pötter R, Kirisits C, Grau C and Lindegaard JC: Adaptive management of cervical cancer radiotherapy. Semin Radiat Oncol 20: 121-129, 2010.
7. Bromley SK, Mempel TR and Luster AD: Orchestrating the orchestrators: Chemokines in control of T cell traffic. Nat Immunol 9: 970-980, 2008.
8. Luster AD, Unkeless JC and Ravetch JV: Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 315: 672-676, 1985.
9. Campanella GS, Colvin RA and Luster AD: CXCL10 can inhibit endothelial cell proliferation independently of CXCR3. PLoS One 5: e12700, 2010.
10. Arenberg DA, Kunsel KL, Polverini PJ, Morris SB, et al: Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 184: 981-992, 1996.
11. Pertl U, Luster AD, Varki NM, Homann D, Gaedicke G, Reisfeld RA and Lode HN: IFN-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy. J Immunol 166: 6944-6951, 2001.
12. Feldman AL, Friedl J, Lans TE, et al: Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts. Int J Cancer 99: 149-159, 2002.
13. Yang LL, Chen P, Luo S, Li J, Liu K, Hu HZ and Wei YQ: CXC-chemokine-ligand-10 gene therapy efficiently inhibits the growth of cervical carcinoma on the basis of its anti-angiogenic and antiviral activity. Biotechnol Appl Biochem 53: 209-216, 2009.
14. Yang LL, Wang BQ, Chen LL, Luo HQ and Wu JB: CXCL10 enhances radiotherapy effects in HeLa cells through cell cycle redistribution. Oncology Lett 3: 383-386, 2012.
15. Xiao F, Wei Y, Yang L, et al: A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin. Gene Ther 9: 1207-1213, 2002.
16. Somassandarem K and El-Deiry WS: Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting region. Oncogene 14: 1047-57, 1997.
17. Li G, Tian L, Hou JM, et al: Improved therapeutic effectiveness by combining recombinant CXC chemokine ligand 10 with cisplatin in solid tumors. Clin Cancer Res 11: 4217-4224, 2005.
18. Han GD, Suzuki K, Koike H, et al: IFN-inducible protein-10 plays a pivotal role in maintaining slit-diaphragm function by regulating podocyte cell-cycle balance. J Am Soc Nephrol 17: 424-453, 2006.
19. Mazumder S, Plesca D and Almasan A: A jekyll and hyde role of angiostatic cytokines in solid tumors. Clin Cancer Res 11: 457-1442, 2007.
20. Kawauchi S, Yamamoto Y, Uchida K, Chochi Y, Kondo T, Oga A and Ishibashi T: Significance of cyclin E and p27 expression in malignant ovarian germ cell tumors: Correlation with the cell proliferation activity and clinicopathologic features. Oncol Rep 16: 1029-1033, 2006.
21. Frosina G: DNA repair and resistance of gliomas to chemotherapy and radiotherapy. Mol Cancer Res 7: 989-999, 2009.
22. Pawlik TM and Keyomarsi K: Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 59: 928-942, 2002.